Precision medicine for acute myeloid leukemia

Expert Review of Hematology

Volumn 9, Issue 1, 2016, Pages 1-3

  Lai, Catherine ^a   Karp, Judith E ^a,b   Hourigan, Christopher S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AML; Leukemia; Measurable residual disease; Minimal residual disease; Mrd; Personalized medicine; Precision medicine; Screening; Sensitivity

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; CANCER PATIENT; CLONAL EVOLUTION; DRUG SENSITIVITY; EX VIVO STUDY; HUMAN; MINIMAL RESIDUAL DISEASE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY; PROGNOSIS;

HUMANS; LEUKEMIA, MYELOID, ACUTE; PRECISION MEDICINE; PROGNOSIS;

EID: 84945556590     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2016.1107471     Document Type: Review

References (22)

1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
2. Klauschen F, Andreeff M, Keilholz U, et al. The combinatorial complexity of cancer precision medicine. Oncoscience. 2014;1(7):504-509.
3. Cancer Genome Atlas Research, N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl J Med. 2013;368(22):2059-2074.
4. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506-510.
5. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29):3681-3687.
6. Grunwald MR, Levis MJ. FLT3 tyrosine kinase inhibition as a paradigm for targeted drug development in acute myeloid leukemia. Semin Hematol. 2015;52(3):193-199.
7. Shih AH, Jiang Y, Meydan C, et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 2015;27(4):502-515.
8. Tyner JW, Yang WF, Bankhead A 3rd, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 2013;73(1):285-296.
9. Pemovska T, Kontro M, Yadav B, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013;3(12):1416-1429.
10. Bennett TA, Montesinos P, Moscardo F, et al. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. Clin Lymphoma Myeloma Leuk. 2014;14(4):305-318.
11. Hourigan CS, Karp JE. Personalized therapy for acute myeloid leukemia. Cancer Discov. 2013;3(12):1336-1338.
12. Kon Kim T, Gore SD, Zeidan AM. Epigenetic therapy in acute myeloid leukemia: current and future directions. Semin Hematol. 2015;52(3):172-183.
13. Ghiaur G, Wroblewski M, Loges S. AML and its microenvironment: a molecular conversation. Semin Hematol. 2015;52(3):200-206.
14. Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol. 2013;10(8):460-471.
15. Hourigan CS, McCarthy P, De Lima M. Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(2):154-163.
16. Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314(8):811-822.
17. Hokland P, Ommen HB, Mule MP, et al. Advancing the minimal residual disease concept in acute myeloid leukemia. Semin Hematol. 2015;52(3):184-192.
18. Marshall G, Blacklock J, Cameron C. STREPTOMYCIN treatment of pulmonary tuberculosis. Br Med J. 1948;2(4582):769-782.
19. Mandrekar SJ, Dahlberg SE, Simon R. Improving clinical trial efficiency: thinking outside the box. Am Soc Clin Oncol Educ Book. 2015;35:e141-e147.
20. Ramos NR, Mo CC, Karp JE, et al. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med. 2015;4(4):665-695.
21. Burnett AK. Treatment of acute myeloid leukemia: are we making progress? ASH Education Program Book. 2012;2012(1):1-6.
22. Estey E. Why is progress in acute myeloid leukemia so slow? Semin Hematol. 2015;52(3):243-248.